Quick Feasibility Assessment to Expand Trial Into Europe Case Study


A clinical stage biotechnology firm wanted to know whether it was feasible and worthwhile to expand their current study into European sites. Their ongoing early phase project in patients with advanced solid tumors is taking place at sites in the United States and Canada. The project had some very specific technology requirements for the site and part of the assessment was to determine if that technology was available at sites in Europe.  In under 5 weeks, Veristat designed and performed the feasibility assessment and provided site and country recommendations to the sponsor.